Regeneron Pharmaceuticals Profile

USD 0.23  0.06%

Exercise or conversion by Roberts William of 529 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Regeneron Pharmaceuticals insider trading alert for exercise of common stock by Roberts William, VP Regul Devel & Clin Safety, on September 25, 2018. This event was filed by Regeneron Pharmaceuticals with SEC on 2009-08-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Regeneron Pharmaceuticals Summary

Regeneron Pharmaceuticals (REGN) is traded on NASDAQ in USA. It is located in 777 Old Saw Mill River Road and employs 6,570 people. The company currently falls under 'Large-Cap' category with current market capitalization of 42.55 B. Regeneron Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 106.03 M outstanding shares of which 2.94 M shares are at this time shorted by private and institutional investors with about 3.56 trading days to cover. REGENERON PHARMAC currently holds about 1.68 B in cash with 2 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.62.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Regeneron Pharmaceuticals Target Price Odds Analysis

Odds Below 390.28HorizonTargetOdds Above 390.28
37.34%30 days 390.28 62.13%
Based on normal probability distribution, the odds of Regeneron Pharmaceuticals to move above current price in 30 days from now is about 62.13% (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Regeneron Pharmaceuticals Top Holders

Regeneron Pharmaceuticals Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Capital World InvestorsCommon Shares6.1 M2.1 B
Blackrock IncCommon Shares6 M2.1 B
View Regeneron Pharmaceuticals Diagnostics

Regeneron Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Regeneron Pharmaceuticals Key Fundamentals

Regeneron Pharmaceuticals Against Markets

Regeneron Pharmaceuticals Current Ratings

Regeneron Pharmaceuticals 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Regeneron Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 6570 people. more
NameRegeneron Pharmaceuticals
President CEO, DirectorLeonard SchleiferView All
Thematic Classifications
Active Investing Ideas
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
Business Address777 Old Saw Mill River Road
Foreign Associates
CIK Number0000872589
Phone914 847 7000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 15, 2018

Regeneron Pharmaceuticals Directors

Regeneron Pharmaceuticals Corporate Directors

Charles Baker Independent Director
Joseph Goldstein Independent Director
Anthony Coles Independent Director
Additionally take a look at Your Equity Center. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.